Dicot Pharma
Dicot Pharma is a Swedish clinical-stage pharmaceutical company developing LIB-01, a novel oral drug candidate targeting erectile dysfunction and premature ejaculation, planning to out-license for global commercialization following Phase 2a.
- Company typePublic
- Founded2015
- HeadquartersUppsala, Sweden
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Dicot Pharma does
Dicot Pharma AB (publ) is a Swedish clinical-stage pharmaceutical company founded in 2015 and headquartered in Uppsala, listed on Nasdaq First North Stockholm under the ticker DICOT since November 2024 (previously on Spotlight Stock Market from 2018). The company is developing a single drug candidate, LIB-01, intended to treat erectile dysfunction (ED) and premature ejaculation (PE). LIB-01 is positioned as the first new oral molecule class for ED in approximately 26 years (since Viagra), with Phase 2a data demonstrating improved erectile function persisting at least 28 days after the first dose, a substantial duration advantage over existing PDE5 inhibitors that require planning before each use. The molecule is protected by four patent families constituting a global IP strategy.
The company's strategy is to develop LIB-01 through Phase 2a under its own auspices and then out-license to larger pharmaceutical partners for Phase 3, registration, and global commercialization, generating revenue through upfront payments, development milestones, and royalties. Dicot is pre-revenue with no current customers or distribution channels; financing to date has come from multiple oversubscribed rights issues (2023, 2024, 2026), a directed guarantor share issue (2024), warrant exercises (TO6 in 2025), and a small Almi Uppsala grant (2023), cumulatively exceeding SEK 450 million. Clinical execution is anchored by Lead Principal Investigator Dr. Harin Padma-Nathan, the original PI for the Viagra and Cialis programs with 110+ clinical trials experience, and a global CRO engaged in December 2025 to run the planned Phase 2b study in the USA and Europe starting in late 2026.
Dicot's go-to-market is therefore licensing-led rather than commercial: the company targets partnership-driven value creation rather than building its own sales infrastructure. The Phase 2b study is the next major catalyst, after which management has signaled it will seek strategic alliances to finance and execute late-stage development and commercialization. With a lean organization of 1-10 employees centered on CEO Elin Trampe, CFO Björn Petersson, CSO Charlotta Gauffin, CBO Håkan Wickholm, CTO Mats Silvander, and Chairman Eva Sjökvist Saers, the company operates as a virtual clinical-development platform focused on de-risking LIB-01 to a partner-acquirable inflection point.
Dicot Pharma firmographics
Firmographics- Name
- Dicot Pharma
- Legal name
- Dicot AB (publ)
- Website
- https://dicotpharma.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Dicot Pharma is a Swedish clinical-stage pharmaceutical company developing LIB-01, a novel oral drug candidate targeting erectile dysfunction and premature ejaculation, planning to out-license for global commercialization following Phase 2a.
- Ownership category
- akta.pro rank
Dicot Pharma industry classification
Industry- Product category
- Erectile Dysfunction Therapeutics
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro industry
- Clinical Development (Phase I–III Trial Design & Execution)
Keywords
Where Dicot Pharma is headquartered
LocationHeadquarters
- HQ city
- Uppsala
- HQ country
- Sweden
- HQ region
- Europe
Offices1 record
Markets served
Dicot Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Licensing Royalties: Dicot Pharma plans to generate revenue through licensing agreements with larger pharmaceutical companies. The company aims to out-license LIB-01 after demonstrating proof-of-concept, receiving upfront payments, milestone payments, and ongoing royalties from commercialization.
- Strategic Pharma Partnerships: The company seeks strategic alliances with established pharmaceutical companies that can finance and conduct late-stage clinical development and global commercialization of LIB-01.
Go-to-market motion2 records
Marketing channels4 records
Dicot Pharma product offering
Product offeringCore offering
Dicot Pharma is developing LIB-01, a single patented drug candidate for the treatment of erectile dysfunction and premature ejaculation. The compound completed Phase 1 with a positive safety profile and an efficacy signal showing improved erectile function persisting 28 days after first dose, with a planned Phase 2b study in the USA and Europe starting in late 2026. The company plans to out-license LIB-01 to larger pharmaceutical companies for late-stage clinical development, registration, and global commercialization.
Product overview
Dicot Pharma is a pharmaceutical company developing a single drug candidate, LIB-01, as a next-generation treatment for sexual dysfunctions including erectile dysfunction and premature ejaculation. The company's product portfolio consists of this one lead compound in clinical development, with the goal of bringing LIB-01 through clinical trials to become a registered pharmaceutical product globally.
Differentiator
Problem solved
Functional benefit
Products and services
- LIB-01 Drug candidate being developed for the treatment of erectile dysfunction and premature ejaculation. LIB-01 is Dicot Pharma's single lead pharmaceutical asset, designed to deliver a longer duration of action and improved safety profile compared with existing oral erectile dysfunction treatments.
Quantifiable outcome
- 50% of men with ED discontinue current treatments
- +2 more outcomes
Companies that use Dicot Pharma
Customer profileSegments1 record
Ideal customer profiles1 record
Dicot Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Dicot Pharma partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Global CRO (Contract Research Organization)coreDicot Pharma signed an agreement with a global CRO firm to conduct the Phase 2b clinical study for its erectile dysfunction drug candidate LIB-01. The study is expected to start in late 2026 and will be conducted in the USA and Europe.
- Dr. Harin Padma-NathancoreWorld leading medical expert in male sexual dysfunctions serving as Lead Principal Investigator for over 110 clinical trials including the Viagra and Cialis programs. Currently serving as Principal Investigator for LIB-01 clinical studies.
Scale indicators7 records
Recent moves8 records
Expansion highlights5 records
Dicot Pharma competitors and assessment
Company assessmentEmerging players
- Marius Pharmaceuticals: US specialty pharma commercializing KYZATREX, an oral testosterone replacement therapy for hypogonadism. Comparable as a small, men's-health-focused pharma pursuing urology and men's health prescribing channels overlapping with LIB-01's target prescriber base.
- Absorption Pharmaceuticals: Developer of Promescent (lidocaine spray) for premature ejaculation. Comparable as a small, focused sexual-health therapeutics company addressing the second indication LIB-01 targets, sharing similar end markets and physician specialties.
Broad incumbents
- VIVUS: Specialty pharma that commercialized avanafil (Stendra) for erectile dysfunction. Comparable as an ED-focused pharma player with experience in PDE5-related commercialization, regulatory pathway, and urology sales channels relevant to LIB-01's eventual launch.
- Coloplast: Global leader in urology and men's health medical devices (including penile implants). Comparable as an established player in the broader ED treatment ecosystem with deep urology channel relationships relevant to any eventual LIB-01 commercialization partner.
- Pfizer (Viagra): Originator of sildenafil (Viagra), the dominant PDE5 inhibitor that LIB-01 is designed to compete against. Pfizer's urology franchise, ED clinical evidence base, and physician relationships set the competitive benchmark LIB-01 must surpass.
- Bayer (Levitra): Marketer of vardenafil (Levitra), a PDE5 inhibitor with established urology sales infrastructure and direct ED clinical experience. Bayer serves as a representative big-pharma comparator and a likely acquirer/partner candidate for novel ED assets.
- Eli Lilly (Cialis): Originator of tadalafil (Cialis), the second major PDE5 inhibitor and the standard-of-care comparator in most modern ED clinical trials. Lilly's lifecycle management of Cialis through combination and OTC pivots frames the competitive landscape LIB-01 enters.
Others
- Sanofi: Large-cap pharma with established consumer health and specialty care channels that could plausibly partner or acquire a novel ED asset like LIB-01. Included as a representative big-pharma potential acquirer/partner given the out-licensing strategy Dicot has explicitly disclosed.
Direct peers
- Apricus Biosciences: Developed Vitaros (alprostadil cream) for erectile dysfunction and was structured as a small clinical/specialty pharma focused on out-licensing and partnership-based commercialization — a near-analog business model to Dicot's planned LIB-01 path.
- Futura Medical: UK-listed clinical-stage company developing Eroxon (MED2002), a topical gel for erectile dysfunction. Highly comparable as a small-cap, single-asset ED developer pursuing regulatory approval and commercialization partnerships in the same indication as Dicot's LIB-01.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights7 records
Customer concentration
Dicot Pharma social profiles
Digital presenceDicot Pharma compliance and trust
Trust signalCompliance1 record
Dicot Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Dicot Pharma leadership team
Management profileNumber of profiles
Profiles6 records
Dicot Pharma funding detail
Funding detailFunding overview
Funding rounds3 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Dicot Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Dicot Pharma
What does Dicot Pharma do?
Dicot Pharma is developing LIB-01, a single patented drug candidate for the treatment of erectile dysfunction and premature ejaculation. The compound completed Phase 1 with a positive safety profile and an efficacy signal showing improved erectile function persisting 28 days after first dose, with a planned Phase 2b study in the USA and Europe starting in late 2026. The company plans to out-license LIB-01 to larger pharmaceutical companies for late-stage clinical development, registration, and global commercialization.
Is Dicot Pharma a public or private company?
Dicot Pharma is a public company. It is classified as public and is currently operating.
When was Dicot Pharma founded?
Dicot Pharma was founded in 2015. It employs 1 to 10 people.
Where is Dicot Pharma based?
Dicot Pharma is headquartered in Uppsala, Sweden, in the Europe region.
How does Dicot Pharma make money?
Two revenue lines are on record. Pharmaceutical Licensing Royalties are the primary driver. The others are strategic Pharma Partnerships.
Who are Dicot Pharma's main competitors?
Emerging players on record are Marius Pharmaceuticals and Absorption Pharmaceuticals. Broad incumbents are VIVUS, Coloplast, Pfizer (Viagra), Bayer (Levitra) and Eli Lilly (Cialis). Sanofi is listed as an others. Direct peers are Apricus Biosciences and Futura Medical.
Does Dicot Pharma have an API?
No public API is recorded for Dicot Pharma.
What industry is Dicot Pharma in?
Dicot Pharma's product category is Erectile Dysfunction Therapeutics. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 32541 and its SIC code is 2834.